Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions.

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All the authors have approved the manuscript and all but Franco Cavaleri have unanimously declared that there is no potential conflict of interest for them. Franco Cavaleri is the owner and CEO of Biologic Pharmamedical Research, the manufacturer of one of the subject treatment protocols, Oncowithanib."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Biologic Publishing Inc./Biologic Pharmamedical Research is the owner of ashwagandha-based, curcuminoid-based and other nutraceutical-based intellectual properties. The author, Franco Cavaleri, is the owner, CEO at Biologic Pharmamedical Research; the organization that funds and executes research on nutraceutical and pharmaceutical pharmacology including research of ashwagandha, withanolide and curcuminoid technologies."